List of Excipients in Branded Drug ALCAINE

« Back to Dashboard

Generic Drugs Containing ALCAINE

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	proparacaine hydrochloride	0998-0016	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	proparacaine hydrochloride	0998-0016	GLYCERIN
Alcon Laboratories Inc	proparacaine hydrochloride	0998-0016	HYDROCHLORIC ACID
Alcon Laboratories Inc	proparacaine hydrochloride	0998-0016	SODIUM HYDROXIDE
Alcon Laboratories Inc	proparacaine hydrochloride	0998-0016	WATER

What are the Most Frequently-Used Excipients in ALCAINE?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	GLYCERIN
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
1	WATER

Last updated: August 9, 2026

ALCAINE is a legacy topical ophthalmic anesthetic containing proparacaine hydrochloride 0.5%. Its principal commercial opportunity is not molecule exclusivity. It is differentiated delivery: preservative-free unit doses, improved multidose packaging, reduced ocular-surface exposure to benzalkonium chloride, longer in-use stability, and workflow products for ophthalmology offices. A generic proparacaine solution faces limited formulation barriers, while a 505(b)(2) product with a new container, preservative system, concentration, or delivery format could support stronger differentiation.

ALCAINE Excipient Strategy and Commercial Opportunities for Proparacaine Ophthalmic Solution

What is ALCAINE and which excipients does it contain?

ALCAINE is Alcon's ophthalmic solution containing proparacaine hydrochloride 0.5%. It is indicated for topical ocular anesthesia during procedures such as tonometry, foreign-body removal, and other short ophthalmic interventions.[1]

The marketed formulation uses a conventional aqueous ophthalmic platform:

Component	Function	Commercial significance
Proparacaine hydrochloride 0.5%	Local anesthetic active ingredient	Established reference drug and generic target
Benzalkonium chloride 0.01%	Antimicrobial preservative	Supports multidose packaging but creates ocular-surface tolerability concerns
Glycerin	Tonicity-adjusting excipient and formulation aid	Helps manage comfort and osmolality
Hydrochloric acid and sodium hydroxide	pH adjustment	Supports chemical stability and ocular tolerability
Purified water	Vehicle	Standard aqueous ophthalmic medium

The labeled pH is maintained within an acidic range, reported by the product labeling as approximately pH 3.5 to 6.0.[1] The formulation is supplied as a sterile ophthalmic solution in a multidose container.

The excipient profile is commercially important because proparacaine itself is an established active ingredient with limited opportunity for composition-of-matter differentiation. Product value therefore depends on sterility, stability, preservative control, container performance, dosing convenience, and ocular tolerability.

What patents protect ALCAINE and proparacaine ophthalmic solution?

Public product labeling identifies ALCAINE as a proparacaine hydrochloride ophthalmic solution but does not establish a current, commercially meaningful patent barrier around the marketed formulation.[1] The product is a legacy ophthalmic anesthetic, and the primary commercial pathway for a conventional equivalent is generally an abbreviated application rather than reliance on a new chemical entity exclusivity period.

Relevant protection may arise from four categories:

1. Composition patents covering a specific proparacaine concentration or excipient combination.
2. Formulation patents covering pH, buffer systems, tonicity, preservative concentration, or stability.
3. Container patents covering unit-dose delivery, multidose valves, preservative-free dispensing, or contamination control.
4. Method-of-use patents covering a defined ophthalmic procedure, dosing regimen, or reduced exposure protocol.

A current patent search should review the FDA Orange Book, USPTO records, international patent databases, and litigation records for proparacaine, ALCAINE, and successor products. The Orange Book is most relevant to approved drug products with listed patents, but it does not capture every potentially relevant formulation, device, manufacturing, or foreign patent.[2]

What is the Orange Book status of ALCAINE?

The Orange Book is the principal U.S. source for patents and regulatory exclusivity listed for approved drug products.[2] A conventional proparacaine ophthalmic solution should not be assumed to have an active Orange Book patent merely because the brand remains marketed.

For a proposed generic, the key regulatory questions are:

• Whether the reference product has an eligible listed patent.
• Whether the applicant must submit a Paragraph IV certification.
• Whether any listed patent has expired, been delisted, or is not relevant to the proposed product.
• Whether the proposed product qualifies as therapeutically equivalent to the reference product.
• Whether the applicant is pursuing an ANDA or a 505(b)(2) application.

No reliable commercial conclusion should be based solely on the brand name. Patent status must be evaluated against the exact reference NDA, listed product, dosage form, and current FDA records.

When does ALCAINE lose exclusivity?

ALCAINE's principal market protection is likely to be regulatory and commercial legacy protection rather than a live molecule patent. Proparacaine hydrochloride has been used in ophthalmic products for decades, which limits the likelihood that a basic proparacaine 0.5% solution remains protected by composition-of-matter rights.

The relevant exclusivity framework is:

Protection type	Relevance to ALCAINE	Expected commercial effect
New chemical entity exclusivity	Not applicable to a long-established active ingredient	No current NCE barrier expected
Five-year NCE patent term	Not applicable	No meaningful effect
Three-year clinical investigation exclusivity	Relevant only to qualifying new changes	Could affect a new formulation or indication
Orphan-drug exclusivity	Not apparent for routine topical anesthesia	No expected effect
Pediatric exclusivity	Product-specific and time-limited	Requires current FDA verification
Listed patent term	Depends on active Orange Book entries	Could delay or complicate ANDA approval
Trade-secret manufacturing know-how	Potentially relevant	May affect process replication but does not block approval by itself

A standard generic would usually target the established active ingredient, concentration, route of administration, dosage form, and clinical use. A differentiated reformulation could face a separate patent analysis if it introduces a new preservative-free presentation, device, or stability technology.

What excipient strategy creates the strongest commercial opportunity?

The strongest strategy is to treat excipients as part of a product platform rather than as low-cost inactive ingredients. The product must address three recurring issues in topical ophthalmology: preservative exposure, multidose contamination, and short procedural use.

Preservative-free unit-dose proparacaine

A preservative-free version in single-use ampoules or blow-fill-seal containers could target:

• Cataract and refractive surgery centers.
• High-volume ophthalmology practices.
• Hospitals seeking to reduce benzalkonium chloride exposure.
• Patients with ocular-surface disease.
• Procedures requiring repeated topical anesthetic use.

The commercial tradeoff is higher packaging cost and greater logistics complexity. The product also needs robust sterile manufacturing, low extractables and leachables, suitable opening characteristics, and clear single-use labeling.

A preservative-free product may be positioned as a differentiated product if it is presented under a new drug application strategy or if the formulation and device materially differ from the reference product. It may not qualify as an interchangeable generic if the container, preservative status, or dosage presentation changes the reference-product relationship.

Reduced-preservative or alternative-preservative multidose systems

A multidose system with lower benzalkonium chloride exposure could preserve the convenience of a bottle while reducing ocular-surface burden. Potential approaches include:

• Lower preservative concentration, if antimicrobial effectiveness and stability are demonstrated.
• Alternative preservatives accepted for ophthalmic use.
• Preservative-compatible valve or pump technology.
• One-way dispensing systems that prevent backflow and contamination.
• Packaging with a microbial barrier that supports preservative-free multidose use.

The main development risks are preservative effectiveness, repeated-use contamination, sorption to container materials, extractables, dose uniformity, and in-use stability. FDA ophthalmic guidance places substantial emphasis on sterility, container closure integrity, microbial control, and product quality.[3]

Improved comfort through pH and tonicity optimization

Proparacaine formulations may produce transient stinging because the formulation pH, active concentration, preservative, and osmolality influence ocular comfort. A new product could investigate:

• A narrower pH range closer to physiologic tear conditions.
• Alternative buffering systems.
• Improved osmolality control.
• Lower excipient burden.
• Reduced preservative concentration.
• Viscosity modification to limit runoff while preserving rapid onset.

The challenge is that pH changes can affect proparacaine stability, solubility, degradation pathways, and preservative performance. A comfort-oriented formulation must also preserve rapid anesthetic onset and short procedural duration.

Viscosity-enhanced delivery

A modestly increased viscosity may extend ocular residence time and reduce dosing loss. Potential excipients include ophthalmic-grade polymers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, or carbomer systems, subject to compatibility and regulatory precedent.

This strategy introduces tradeoffs:

• Increased residence time may improve procedural coverage.
• Higher viscosity may blur vision or slow drug diffusion.
• Polymer interactions may alter dose uniformity.
• Drop size and bottle performance may change.
• Sterilization and filtration may become more difficult.
• The product could shift from a simple solution toward a more complex formulation category.

A viscosity-based patent would need a narrow and reproducible claim set. Broad claims to "a viscous proparacaine solution" would face prior-art risk. Stronger claims could focus on a defined polymer concentration, viscosity range, preservative-free presentation, stability profile, or measured pharmacodynamic outcome.

What formulations are protected by potential ALCAINE follow-on patents?

The most defensible follow-on patent opportunities are formulation and device combinations with measurable technical performance.

Potential claim area	Example technical limitation	Patent strength
Preservative-free formulation	Proparacaine 0.5% with defined pH, osmolality, and stability	Moderate if unexpected stability is shown
Multidose preservative-free bottle	One-way valve or microbial-barrier dispensing system	Moderate to strong if device performance is demonstrated
Reduced-BAC formulation	Lower benzalkonium chloride level with preserved antimicrobial effectiveness	Moderate
Comfort formulation	Defined pH, osmolality, and reduced stinging endpoint	Moderate if supported by comparative data
Viscosity-controlled solution	Specific polymer, viscosity range, and stability profile	Moderate
Unit-dose packaging	Blow-fill-seal container with defined extractables and dose delivery	Moderate
Combination procedural kit	Proparacaine with a sterile applicator or procedure-specific packaging	Variable
Manufacturing process	Sterile filtration, filling, or impurity-control process	Strong only where process parameters produce a non-obvious result

Patentability will depend on novelty, non-obviousness, written description, enablement, and freedom to operate. Excipient selection alone is often vulnerable when the ingredient is already listed in FDA's Inactive Ingredient Database or commonly used in ophthalmic products.[4]

How does an ALCAINE generic compare with a reformulated 505(b)(2) product?

Attribute	Conventional generic	Reformulated 505(b)(2) product
Active ingredient	Proparacaine hydrochloride	Proparacaine hydrochloride
Formulation	Closely aligned with reference product	May use new pH, preservative, viscosity, or device
Regulatory pathway	ANDA	NDA under 505(b)(2)
Clinical development	Limited comparative requirements if bioequivalence is established	May require bridging, safety, usability, or clinical data
Price position	Usually lower than brand	Can support premium pricing if differentiated
Patent opportunity	Limited	Greater opportunity for formulation and device claims
Manufacturing cost	Lower for standard bottle	Higher for sterile unit-dose or advanced container
Market access	Pharmacy and office procurement	Specialty, institutional, and procedure-based channels
Main risk	Price erosion and therapeutic-equivalence competition	Development cost and reimbursement acceptance

A conventional ANDA has the clearest path if the goal is volume and low manufacturing cost. A 505(b)(2) strategy is more attractive when the product solves a documented problem, such as preservative exposure or multidose contamination, and can obtain premium pricing from high-value procedural settings.

What FDA regulatory status applies to ALCAINE follow-on products?

A proparacaine ophthalmic solution is regulated as a sterile ophthalmic drug. The regulatory package must address:

• Identity, strength, purity, and impurities.
• Sterility assurance.
• Container closure integrity.
• Preservative effectiveness where applicable.
• pH and osmolality.
• Particulate matter.
• Extractables and leachables.
• Stability after opening.
• Drop size and delivered volume.
• Microbial control during repeated use.
• Compatibility with the proposed container and closure.

For an ANDA, the applicant generally seeks pharmaceutical equivalence and bioequivalence to the reference product. Ophthalmic products may require product-specific evidence because systemic pharmacokinetic measurements do not always fully describe local ocular performance.

A 505(b)(2) application can rely in part on FDA's prior findings for proparacaine while supporting the new formulation, device, indication, or dosage presentation with additional data. The regulatory benefit is flexibility. The cost is a larger evidence package and potentially greater patent exposure if the product claims a new technical feature.

Which companies are competing with ALCAINE?

The competitive set includes:

• Generic proparacaine hydrochloride ophthalmic solution manufacturers.
• Suppliers of ophthalmic anesthetic products based on tetracaine or other topical anesthetics.
• Hospitals and ambulatory surgery centers using facility-prepared or procedure-specific ophthalmic protocols.
• Developers of preservative-free ophthalmic delivery systems.
• Manufacturers of sterile unit-dose ophthalmic containers.

Competition is driven by procurement price, availability, sterile supply reliability, bottle performance, preservative profile, and wholesaler coverage. Proparacaine products also compete indirectly with tetracaine ophthalmic products in clinical settings, although the products are not interchangeable solely because both are topical anesthetics.

ALCAINE's strongest remaining commercial attributes are brand recognition, established clinical use, and broad procedural familiarity. Its weaknesses are the conventional preserved multidose format and limited product differentiation at the formulation level.

What generic entry risks exist for ALCAINE?

Price erosion

The principal risk is rapid price erosion after multiple ANDA approvals. A conventional solution is relatively difficult to differentiate and may become a commodity product.

Formulation substitution

A generic with a preservative-free unit-dose format may gain institutional share even if it does not directly replace the branded multidose product in every channel.

Supply disruption

Sterile ophthalmic manufacturing is vulnerable to facility shutdowns, quality investigations, container shortages, and fill-finish constraints. A reliable supplier can win share despite limited brand differentiation.

Patent and device disputes

A follow-on product using a proprietary multidose valve, preservative system, or packaging architecture may face device or formulation patent claims even if the active ingredient is unprotected.

Regulatory delay

Deficiencies involving sterility, particulate matter, container closure integrity, or preservative effectiveness can delay approval and increase launch cost.

What licensing deals could support an ALCAINE follow-on product?

Licensing opportunities are more likely to involve technology than the proparacaine molecule. Relevant targets include:

• Preservative-free multidose dispensing systems.
• Blow-fill-seal ophthalmic packaging.
• Low-extractables container materials.
• Antimicrobial container technologies.
• Ophthalmic viscosity and mucoadhesive platforms.
• Sterile filling and terminal sterilization expertise.
• Regional marketing rights for hospital ophthalmology products.

A technology license is most valuable when it provides a defensible device claim, documented microbial-control performance, or a regulatory package with precedent in ophthalmic products. A simple license to a commonly used excipient is unlikely to create durable market protection.

How strong is the patent estate for ALCAINE?

The legacy ALCAINE product appears more exposed to generic competition than to an active composition-of-matter patent barrier. The likely strength ranking is:

1. Basic proparacaine 0.5% aqueous solution: low patent differentiation.
2. Standard glycerin and benzalkonium chloride formulation: low to moderate, depending on exact claim scope.
3. Preservative-free multidose system: moderate to strong if device claims are valid and enforceable.
4. Procedure-specific kit or delivery system: moderate, with commercial value depending on adoption.
5. Improved comfort formulation: moderate, but data-intensive.
6. Manufacturing process patents: variable, with value concentrated in supply reliability and impurity control.

Patent value will depend less on the existence of a proparacaine patent and more on whether a follow-on product creates a technically distinct product that cannot be easily designed around.

What is the revenue exposure from ALCAINE generic entry?

Brand revenue exposure depends on the share of sales generated by:

• U.S. pharmacy dispensing.
• Hospital and ambulatory surgery contracts.
• Ophthalmology office purchasing.
• International markets.
• Brand-sensitive prescribers.
• Procedure kits and bundled procurement.

A standard generic launch would likely affect price first in high-volume procurement channels. A preservative-free or advanced-container product could avoid direct price competition by targeting institutions that value ocular-surface tolerability, single-use sterility, or workflow efficiency.

The most attractive commercial model is a segmented portfolio:

Product	Target customer	Strategic role
Standard proparacaine 0.5% bottle	Retail and office use	Volume and formulary access
Preservative-free unit dose	Surgery centers and hospitals	Premium differentiation
Preservative-reduced multidose bottle	Chronic ocular-surface-sensitive users	Intermediate positioning
Procedure kit	Institutional purchasers	Workflow and bundling
International presentation	Distributor and tender markets	Geographic expansion

What geographic coverage matters for proparacaine products?

The United States is the most relevant market for Orange Book, ANDA, and 505(b)(2) analysis. Europe, Canada, Japan, China, and emerging markets require separate review of:

• National marketing authorizations.
• Local patent registers.
• Supplementary protection certificates where applicable.
• Data and market exclusivity.
• Device registration requirements.
• Preservative restrictions.
• Hospital tender rules.
• Local sterile manufacturing requirements.

A product designed around preservative-free packaging may have broader international appeal because regulatory and clinical concern about benzalkonium chloride is not limited to the U.S. The commercial case is strongest where ophthalmology practices use high procedure volumes and where single-use sterile products command a procurement premium.

Key Takeaways

• ALCAINE contains proparacaine hydrochloride 0.5% in a conventional preserved aqueous ophthalmic solution.
• The principal excipient issue is benzalkonium chloride exposure in a multidose presentation.
• A basic proparacaine generic is likely to face substantial price competition and limited patent differentiation.
• The strongest commercial opportunity is a preservative-free unit-dose or preservative-free multidose product with validated microbial control.
• pH, osmolality, viscosity, container closure, and in-use stability are the most relevant formulation-development levers.
• A 505(b)(2) strategy is more appropriate than a conventional ANDA when the product introduces a new delivery system, preservative profile, or clinically meaningful tolerability benefit.
• Potential patent value lies in formulation-device combinations, not in the legacy active ingredient.
• Sterile manufacturing reliability and packaging performance may create more durable commercial advantage than excipient selection alone.

FAQs About ALCAINE Excipient and Patent Opportunities

Can benzalkonium chloride be removed from ALCAINE?

Yes. A preservative-free formulation can be developed in a unit-dose container or a validated multidose system with microbial-barrier technology. Removing benzalkonium chloride requires new stability, sterility, container, and in-use testing.

Is glycerin essential to the ALCAINE formulation?

Glycerin is a formulation excipient that can contribute to tonicity and product performance, but a follow-on developer may evaluate alternative tonicity agents. Any substitution must preserve stability, comfort, sterility, and dose uniformity.

Could a new ALCAINE formulation receive a separate patent?

Yes. A patent could cover a specific excipient combination, pH range, preservative-free container, viscosity profile, stability result, or delivery system. The claims must overcome prior art involving established ophthalmic excipients and proparacaine formulations.

Would a preservative-free proparacaine product be therapeutically equivalent to ALCAINE?

Not automatically. Therapeutic-equivalence status depends on the regulatory pathway, formulation, dosage form, container, labeling, and FDA findings. A materially different presentation may require a 505(b)(2) application rather than an ANDA.

Does ALCAINE compete with tetracaine ophthalmic products?

Yes, at the procedure level. Both are topical ophthalmic anesthetics, but they have different active ingredients, labeling, clinical use patterns, and regulatory records. Procurement decisions may depend on onset, duration, tolerability, availability, and price.

References

1. DailyMed. (n.d.). ALCAINE: Proparacaine hydrochloride ophthalmic solution, USP 0.5%. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2008). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services.
5. United States Pharmacopeia. (2023). General chapter <771>, Ophthalmic products. United States Pharmacopeial Convention.